Ocular adnexal follicular lymphoma: a multicenter international study.

Abstract

IMPORTANCE:

The clinical features of the follicular subtype of ocular adnexal lymphoma (OAL) have not been previously evaluated in a large cohort.

OBJECTIVE:

To characterize the clinical features of follicular OAL.

DESIGN, SETTING, AND PARTICIPANTS:

We performed a retrospective multicenter study that involved 6 eye cancer centers from January 1, 1980, through December 31, 2010. A total of 105 patients with follicular OAL were identified, of which 7 patients were excluded because of missing clinical data. The median follow-up time was 52 months (range, 13-118 months).

MAIN OUTCOMES AND MEASURES:

Overall survival, disease-specific, and progression-free survivals were the primary end points.

RESULTS:

Ninety-eight eligible patients with follicular OAL were included; 60 (61%) were women. The median patient age was 63 years (range, 32-96 years). Sixty-nine patients (70%) had primary OAL, 19 (19%) had OAL in conjunction with a concurrent systemic lymphoma, and 10 (10%) presented with an ocular adnexal relapse. The lacrimal gland (28%), conjunctiva (28%), and orbit (28%) were the most frequently involved sites. Of the 69 patients with primary follicular lymphoma, 38 (55%) presented with Ann Arbor stage IE lymphoma, and 31 (45%) had stage IIE lymphoma. Patients with disseminated lymphoma had stage IIIE (9 of 19 [47%]) and stage IV (10 of 19 [53%]) disease, whereas patients with a relapse of systemic lymphoma presented with stage IE (8 of 10 [80%]), stage IIE (1 of 10 [10%]), and stage IIIE (1 of 10 [10%]) disease. Patients with primary follicular lymphoma (n = 69) and those with isolated ocular relapse (n = 9) were treated with external beam radiation therapy (EBRT) (35 of 78 [45%]) or EBRT plus chemotherapy (22 of 78 [28%]). Patients presenting with stage IIIE-IV follicular lymphoma (n = 20) most frequently received chemotherapy (9 of 20 [45%]) or EBRT plus chemotherapy (4 of 20 [20%]). The 10-year overall survival for the entire study cohort was 60%. Primary patients treated with EBRT had a better disease-specific survival compared with patients receiving ERBT plus chemotherapy (10-year disease-specific survival, 94% vs 40%; P = .02 by log-rank test).

CONCLUSIONS AND RELEVANCE:

Follicular OAL was more commonly found in elderly female patients. These tumors were equally noted to involve the conjunctiva, lacrimal gland, and orbit. Patients with ocular adnexal follicular lymphoma primarily treated with EBRT had a more favorable long-term disease-specific survival.

• Authors: Peter K Rasmussen, Sarah E Coupland, Paul T Finger, Gerardo F Graue, Hans E Grossniklaus, Santosh G Honavar, Penny McKelvie, Kaustubh Mulay, Jan U Prause, Elisabeth Ralfkiaer, Lene D Sjö, Steffen Heegaard
• Journal: JAMA ophthalmology (JAMA Ophthalmol) Vol. 132 Issue 7 Pg. 851-8 (Jul 2014) ISSN: 2168-6173 [Electronic] United States
• PMID: 24763920 (Publication Type: Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't)

Chemical References

• Antineoplastic Agents
• Biomarkers, Tumor
• Neoplasm Proteins

Topics

• Adult
• Aged
• Aged, 80 and over
• Antineoplastic Agents (therapeutic use)
• Biomarkers, Tumor (analysis)
• Biopsy
• Cohort Studies
• Combined Modality Therapy
• Conjunctival Neoplasms (diagnosis, mortality, therapy)
• Disease-Free Survival
• Eye Neoplasms (diagnosis, mortality, therapy)
• Eyelid Neoplasms (diagnosis, mortality, therapy)
• Female
• Humans
• Internationality
• Lacrimal Apparatus Diseases (diagnosis, mortality, therapy)
• Lymphoma, Follicular (diagnosis, mortality, therapy)
• Male
• Middle Aged
• Neoplasm Proteins (analysis)
• Neoplasm Staging
• Orbital Neoplasms (diagnosis, mortality, therapy)
• Proton Therapy
• Retrospective Studies
• Survival Rate